Vertex Pharma (VRTX) – Momentum Movers
-
Vertex Pharma (VRTX) Climbs 7% Following Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
-
Vertex’s (VRTX) VX-147 Data Well Above Expectations, Potential $1B Opportunity - Analyst
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to VRTX Stock Lookup